Internet Archive Scholar

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

K. Bridges, M. Telfer, Kenneth Ataga, E. Orringer, C. Hoehner, S. Hernandez, S. Valdez, D. Temple, S. Shurin, A. Johnson-Telfair, W. Hagar, E. Vichinsky (+98 others)
2010

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (349.9 kB)
https://web.archive.org/web/20201210192021/https://cdr.lib.unc.edu/downloads/6395wd727

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydroxyurea. The purpose of this follow-up was to search for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 95% confidence intervals were calculated, or tests were
more » ... ted at α = 0.05 level (p-value <0.05 for statistical significance). Although the death rate in the overall study cohort was high (43.1%; 4.4 per 100 person-years), mortality was reduced in individuals with long-term exposure to hydroxyurea. Survival curves demonstrated a significant reduction in deaths with long-term exposure. Twenty-four percent of deaths were due to pulmonary complications; 87.1% occurred in patients who never took hydroxyurea or took it for <5 years. Stroke, organ dysfunction, infection and malignancy were similar in all groups. Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality.
doi:10.17615/y997-wd39 fatcat:lbwmexmm4vemtd5a6q3oocir5a
Citation

K. Bridges, M. Telfer, Kenneth Ataga, E. Orringer, C. Hoehner, S. Hernandez, S. Valdez, D. Temple, S. Shurin, A. Johnson-Telfair, W. Hagar, E. Vichinsky, Wally Smith, Martin H. Steinberg, K. Kleman, W. Rosse, L. Waller, Y. Barber, J. Chow, P. Gascon, C. Winograd, P. Di Paolo, M. Hui, J. Moshang, N. Olivieri, L. Dorn, J. Siteman, S. Embury, J. Eckman, Samir K. Ballas, A. Anderson, L. White, T. Harrington, N. Talischy-Zahed, D. Shaw, B. Scott, Myron A. Waclawiw, W. Labrousse, B. Adler, G. Phillips, C. Bigelow, F. Danny Armstrong, K. Chiarucci, S. Childerie, K. McLaughlin, E. Mandell, Laura DeCastro, S. Claster, V. Knors, S. Gargiulo, S. Jones, B. Tynan, Y. Saunthararajah, T. Saunders, B. Maddox, E. Hackney-Stevens, L. Keverline, D. Gardner, E. Carter-Randall, B. Schmidt, A. Tracy, D. Davies, T. Carlos, Abdullah Kutlar, H. Finke, C. Nwokolo, E. Perlin, O. C. Onyekwere, M. Okam, D. Peace, P. Milner, M. Koshy, M. Sheikhai, L. Daitch, Paul Swerdlow, G. Pendarvis, R. Harrell, E. Case, A. Brenner, J. H. Bailey, D. Strayhorn, J. Prchal, G. Ramirez, H. Dosik, A. Platt, M. McGee, N. Lewis, Oswaldo Castro, A. Palmer, E. Wilkes, J. Braddock, V. Sabahi, C. Pegelow, R. Bellevue, T. McArdle, R. O'Brien, K. Williams, L. Usry, L. Eskridge, B. Berman, G. E. Allen, A. Earles, M. Bryan, A. Davis, E. M. Rodriguez, H. Souffrant, K. Genther, William F. McCarthy, A. Roundtree-Schmotzer, P. Ryans. "The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up." (2010)